HDAC Screening identifies the HDAC Class I Inhibitor Romidepsin as a promising Epigenetic Drug for Biliary Tract Cancer

Christian Mayr; Tobias Kiesslich; Sara Erber; Dino Bekric; Heidemarie Dobias; Marlena Beyreis; Markus Ritter; Tarkan Jager; Bettina Neumayer; Paul Winkelmann; Eckhard Klieser; Daniel Neureiter

doi:10.1096/fasebj.2021.35.S1.05128

HDAC Screening identifies the HDAC Class I Inhibitor Romidepsin as a promising Epigenetic Drug for Biliary Tract Cancer

Christian Mayr, Tobias Kiesslich, Sara Erber, Dino Bekric, Heidemarie Dobias, Marlena Beyreis, Markus Ritter, Tarkan Jager, Bettina Neumayer, Paul Winkelmann, Eckhard Klieser, Daniel Neureiter

Publikation: Beitrag in Fachzeitschrift › Abstrakt (Zeitschrift) › Begutachtung

8 Quellenangaben (Web of Science)

Originalsprache	Englisch
Seitenumfang	2
Fachzeitschrift	FASEB journal : official publication of the Federation of American Societies for Experimental Biology.
DOIs	https://doi.org/10.1096/fasebj.2021.35.S1.05128
Publikationsstatus	Veröffentlicht - Mai 2021
Veranstaltung	Experimental Biology Meeting - Dauer: 27 Apr. 2021 → 30 Apr. 2021

Zugriff auf Dokument

10.1096/fasebj.2021.35.S1.05128

Andere Dateien und Links

Datensatz in Web of Science anzeigen

Dieses zitieren

Mayr, C., Kiesslich, T., Erber, S., Bekric, D., Dobias, H., Beyreis, M., Ritter, M., Jager, T., Neumayer, B., Winkelmann, P., Klieser, E., & Neureiter, D. (2021). HDAC Screening identifies the HDAC Class I Inhibitor Romidepsin as a promising Epigenetic Drug for Biliary Tract Cancer. FASEB journal : official publication of the Federation of American Societies for Experimental Biology. https://doi.org/10.1096/fasebj.2021.35.S1.05128

@article{16f2ed8f8a804c3a9feb0019c3eccec8,

title = "HDAC Screening identifies the HDAC Class I Inhibitor Romidepsin as a promising Epigenetic Drug for Biliary Tract Cancer",

author = "Christian Mayr and Tobias Kiesslich and Sara Erber and Dino Bekric and Heidemarie Dobias and Marlena Beyreis and Markus Ritter and Tarkan Jager and Bettina Neumayer and Paul Winkelmann and Eckhard Klieser and Daniel Neureiter",

year = "2021",

month = may,

doi = "10.1096/fasebj.2021.35.S1.05128",

language = "English",

journal = " FASEB journal : official publication of the Federation of American Societies for Experimental Biology.",

issn = "0892-6638",

publisher = "Wiley Verlag ",

note = "Experimental Biology Meeting ; Conference date: 27-04-2021 Through 30-04-2021",

}

Mayr, C , Kiesslich, T, Erber, S, Bekric, D , Dobias, H, Beyreis, M, Ritter, M, Jager, T, Neumayer, B, Winkelmann, P, Klieser, E & Neureiter, D 2021, 'HDAC Screening identifies the HDAC Class I Inhibitor Romidepsin as a promising Epigenetic Drug for Biliary Tract Cancer', FASEB journal : official publication of the Federation of American Societies for Experimental Biology. https://doi.org/10.1096/fasebj.2021.35.S1.05128

HDAC Screening identifies the HDAC Class I Inhibitor Romidepsin as a promising Epigenetic Drug for Biliary Tract Cancer. / Mayr, Christian ; Kiesslich, Tobias; Erber, Sara et al.
in: FASEB journal : official publication of the Federation of American Societies for Experimental Biology., 05.2021.

Publikation: Beitrag in Fachzeitschrift › Abstrakt (Zeitschrift) › Begutachtung

TY - JOUR

T1 - HDAC Screening identifies the HDAC Class I Inhibitor Romidepsin as a promising Epigenetic Drug for Biliary Tract Cancer

AU - Mayr, Christian

AU - Kiesslich, Tobias

AU - Erber, Sara

AU - Bekric, Dino

AU - Dobias, Heidemarie

AU - Beyreis, Marlena

AU - Ritter, Markus

AU - Jager, Tarkan

AU - Neumayer, Bettina

AU - Winkelmann, Paul

AU - Klieser, Eckhard

AU - Neureiter, Daniel

PY - 2021/5

Y1 - 2021/5

UR - https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=pmu_pure&SrcAuth=WosAPI&KeyUT=WOS:000669893105308&DestLinkType=FullRecord&DestApp=WOS

U2 - 10.1096/fasebj.2021.35.S1.05128

DO - 10.1096/fasebj.2021.35.S1.05128

M3 - Abstract (Journal)

SN - 0892-6638

JO - FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

JF - FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

T2 - Experimental Biology Meeting

Y2 - 27 April 2021 through 30 April 2021

ER -